Herpes Simplex
Conditions
Keywords
Herpes simplex candidate vaccine, Herpes simplex
Brief summary
The purpose of the study is to evaluate the safety of Herpes Simplex candidate vaccine (gD2t) with adjuvant and its efficacy to prevent genital herpes disease in HSV positive or negative consorts of subjects with genital herpes disease.
Detailed description
This study was monitored by a Data Safety Monitoring Board At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham
Interventions
BIOLOGICALHerpes simplex candidate vaccine- adjuvanted GSK208141
Intramuscular injection, 3 doses
BIOLOGICALPlacebo injection
Intramuscular injection, 3 doses
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Between 18 and 45 years of age at the time of first vaccination * Written informed consent * Females of childbearing potential must have a negative pregnancy test at enrollment and be using an accepted method of birth control * The volunteers must have a regular sexual partner with genital herpes disease confirmed by medical history
Exclusion criteria
* Any previous history of or current clinical signs or symptoms of genital herpes disease. * Any previous vaccination against herpes simplex. * Any previous administration of MPL. * History of herpetic keratitis. * History of erythema multiforme. * Female subjects who are pregnant, lactating or planning a pregnancy before one month after the last vaccine dose. * Patient is immuno-compromised or is receiving immuno-modifying therapy of any kind. Topical corticoid therapy is allowed. * HIV positive at the time of enrollment * Clinical signs of acute or febrile illness at the time of entry into the study. * Any continuous suppressive antiviral oral therapy within the 6 months prior to entry. * Any administration of immunoglobulins during the vaccination course or within one month prior to the first vaccination. * Any vaccine administration less than one week before or after a study vaccination. * Previous known hypersensitivity to vaccination or to any component of the vaccine. * Simultaneous participation in any other clinical trial of an investigational compound. * Recent history of alcoholism or drug abuse * Recent clinical history or evidence of significant hepatic disease * Recent clinical history or evidence of renal dysfunction * Life-threatening or serious cardiac (NYHA grades III-IV), gastrointestinal, haematological or immunological disorder which, in the opinion of the investigator, would preclude entry into the study. * Inability or unwillingness to comply with the protocol or not expected to complete the study period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare between herpes simplex vaccine (gD2t with adjuvant) and placebo the general safety of the vaccine by recording all the unsolicited adverse experiences | During the 7 month vaccination period |
| To evaluate the protective efficacy of gD2t with adjuvant to prevent acquisition of genital herpes disease in healthy female adults who are HSV seronegative or HSV seropositive at baseline | Survival analysis beginning at Month 0 |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the protective efficacy of the gD2t with adjuvant vaccine to prevent acquisition of genital herpes disease in healthy female adults who are HSV seronegative or HSV-1 seropositive at baseline | After 3 doses of vaccine (between months 7 and 19) |
| To evaluate the protective efficacy of the gD2t with adjuvant vaccine to prevent symptoms of genital herpes disease in healthy female adults who are HSV seronegative at baseline | Survival analysis beginning at Month 0 |
| To evaluate the protective efficacy of gD2t with adjuvant vaccine to prevent acquisition of genital herpes disease in healthy female adults who are HSV seronegative at baseline | Survival analysis beginning at Month 0 |
| To evaluate the protective efficacy of gD2t with adjuvant vaccine to prevent HSV infection in healthy female adults who are HSV seronegative at baseline. | — |
| To evaluate the protective efficacy of gD2t with adjuvant vaccine to prevent HSV infection in healthy female adults who are HSV seronegative or HSV-1 seropositive at baseline | — |
| To evaluate the protective efficacy of the gD2t with adjuvant vaccine to prevent acquisition of genital herpes disease in healthy male and female adults who are HSV seronegative or HSV-1 seropositive at baseline | Survival analysis beginning at Month 0 |
Outcome results
None listed